Abstracts tagged "autoimmune diseases"

Abstract Number: 0775 • ACR Convergence 2024
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Löhr⁸, Nicolas Schleinitz⁹, Lingli Dong¹⁰, Hisanori Umehara¹¹, Marco Lanzillotta¹², Zachary Wallace¹³, Mikael Ebbo¹⁴, George Webster¹⁵, Ferran Martinez Valle¹⁶, Manu Nayar¹⁷, Vinciane Rebours¹⁸, Cory Perugino¹⁹, Xinxin Dong²⁰, Yanping Wu²⁰, Nishi Rampal²⁰ and Daniel Cimbora²⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Ospedale San Raffaele, Milan, Italy, ⁶University of Occupational and Environmental Health, Osaka, Japan, ⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹¹Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, ¹²IRCCS Ospedale San Raffaele, Milano, Italy, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴Aix-Marseille Université, Marseille, France, ¹⁵University College Hospital London, London, United Kingdom, ¹⁶Vall d’Hebron Hospital, Barcelona, Spain, ¹⁷Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Beaujon Hospital, Université Paris-Cité, France, ¹⁹Massachusetts General Hospital, Boston, MA, ²⁰Amgen Inc., Thousand Oaks, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 0860 • ACR Convergence 2024
Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases
Xiangyi Shen¹, Xu Jiang², Yangzhige He² and Huaxia Yang³, ¹Tsinghua University, Beijing, China, ²National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Autoimmune diseases (AIDs) increase the risk of cancer and impose a substantial socioeconomic burden worldwide. However, the biological characteristics of cancer as a comorbidity…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
Abstract Number: 1107 • ACR Convergence 2024
Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
Carine Moezinia¹, Jan Nouza², Beatrice Hornstein-Lasry², Luai Kawar², Asim Khan² and Jessica Manson², ¹University College London Hospital, London, England, United Kingdom, ²University College London Hospital, London, United Kingdom
Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
Abstract Number: 1304 • ACR Convergence 2024
Assessing Knowledge and Aptitude in Antinuclear Antibody Testing Among Internal Medicine Residents
Dania Kaur¹, Fizza Zulfiqar², Akanksha Sharma³, Muhammad Bilal⁴, Rida Fatima⁴ and Abhinav Vyas⁵, ¹North Alabama Medical Center, Muscle Shoals, AL, ²Trinity Health Oakland/Wayne State University, Pontiac, MI, ³UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Vanderbilt University Medical Center, Nahville, TN
Background/Purpose: Testing for antinuclear antibodies (ANA) is essential for diagnosing autoimmune and rheumatologic diseases. The testing has become increasingly popular in primary and specialized clinics,…
Abstract Number: 1533 • ACR Convergence 2024
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Shrishti Tyagi¹, Kevin Hart¹, Ryan Eberwine², Angus Sinclair¹, Albert Candia¹, Bruce Keyt¹, Merle Elloso², Maya Kotturi¹ and Mary Beth Harler¹, ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
Abstract Number: 1659 • ACR Convergence 2024
Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking
Koen Venken¹, Matthias Jarlborg¹, Frederik Stevenaert², Thomas Malfait³, Carolien Vlieghe¹, Yann Abraham², Teddy Manuello¹, Tine Decruy¹, Stijn Van Hee¹, Hans Wils², Pieter Peeters², Philippe Carron⁴, Filip Van den Bosch³, Viggo Van Tendeloo², Bart Lambrecht¹, Ruth Wittoek⁵, Peggy Jacques⁶ and Dirk Elewaut⁷, ¹VIB Center for Inflammation Research - Ghent University, Ghent, Belgium, ²Janssen Research and Development, Beerse, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴UZ Gent, Gent, Belgium, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ⁶University Hospital of GHent, Gent, Belgium, ⁷Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Cigarette smoking has been associated with the production of anti-citrullinated protein antibodies (ACPA) and an increased risk of developing rheumatoid arthritis (RA) in individuals…
Abstract Number: 1787 • ACR Convergence 2024
Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis
Andrea Daamen¹, Kathryn Kingsmore², Prathyusha Bachali³, Nan Shen⁴, Amrie Grammer⁵ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, ³AMPEL BioSolutions, Redmond, WA, ⁴Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), ⁵AMPEL LLC, Charlottesville, VA
Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
Abstract Number: 1863 • ACR Convergence 2024
Human Endogenous Retroviruses Promote the Aberrant T Cell Differentiation in Systemic Lupus Erythematosus
Xiaoli Min¹, Jiali Wu², Yaqin Yu³, Qianjin Lu⁴ and Ming Zhao⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China (People's Republic), ²Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³Central South University, Changsha, China (People's Republic), ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic)
Background/Purpose: Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and systems. The complex pathogenesis of SLE involved the abnormal activation of CD4+T cells and DNA hypomethylation modification. Human endogenous retroviruses (HERVs)…
Abstract Number: 1996 • ACR Convergence 2024
Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review
Elizabeth Wang¹, Genna Braverman², Nilasha Ghosh³, Karmela Kim Chan², Jean-Marie Michot⁴ and Anne Bass⁵, ¹Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Gustave Roussy, Villejuif, France, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) have greatly improved cancer outcomes but they often cause immune-related adverse vents (irAE). "Sarcoid-like" and other granulomatous reactions (GR) are…
Abstract Number: 2208 • ACR Convergence 2024
Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Aparna Swaminathan¹, Jeremy Weber², Jamie Todd³, Scott Palmer³, Megan Neely³, Peide Li⁴ and Ann Chauffe⁵, and on behalf of the ILD-PRO Registry investigators, ¹Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, NC, ²Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, North Carolina, USA; Duke University Medical Center, Durham, North Carolina, USA, Durham, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT
Background/Purpose: The ILD-PRO Registry is a multicenter US registry of patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We…
Abstract Number: 2422 • ACR Convergence 2024
Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Anil Bagri¹, Alec Witty¹, Amanda Sims¹, Allan Williams¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Yang Wang¹, Stacey Moreno¹, Allison Aguilar¹, Cara Bickers¹, Yijia Pan¹, Amber Chang¹, Christine Chen¹, Karina Palomares¹, Lauren Fong¹, Nicholas Brookhouser¹, Berhan Mandefro¹, Sajid Mahmood¹, Ramesh Janani¹, Ramzey Abujarour¹, Tom Lee¹, Raedun Clarke¹, Rebecca Elstrom¹, Frank Cichocki², Lilly Wong¹, Betsy Rezner¹, Jode Goodridge¹, Jeffrey Miller² and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Department of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Unprecedented clinical data have recently shown that patients with certain highly refractory autoimmune diseases (AI Dz) treated with conditioning chemotherapy (CCT) and autologous anti-CD19…
Abstract Number: 2577 • ACR Convergence 2024
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Joan Merrill¹, Amit Saxena², Martin Aringer³, Yoshiya Tanaka⁴, Xiaofeng Zeng⁵, Peter Wung⁶, Ling Cheng⁶, Thao Doan⁶, Shelly Kafka⁶, David DCruz⁷ and Kristin D'Silva⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ²NYU Grossman School of Medicine, New York, NY, ³University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ⁶AbbVie Inc., North Chicago, IL, ⁷The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: 0011 • ACR Convergence 2024
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Brandon Kwong¹, Daniel Anaya¹, Soo Park², Sunetra Biswas², Jeevitha Jeevan², Jesus Banuelos², Madison Strobach², Nicole Khoshnoodi¹, Timothy Klasson¹, Santiago Foos-Russ¹, Jennifer Zeng¹, Candice Gibson³, Jazmin Bravo², Simone Sandoval¹, Shouvonik Sengupta¹, Shairaz Shah¹, Tom Van Blarcom² and Karen Walker², ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emeryville, ³Kyverna Therapeutics, Inc., Emerybille
Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].